PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research

Abstract 2519: Characterization of BRAF fusions and their therapeutic and resistance implications in NSCLC

View Full Paper
Ask AI
Bookmark
Share

Authors

KWK R WangCYChao YiXNXiong Ning

Discussion

Loading...

Member takes

Overview

Analyzes BRAF fusions in NSCLC, highlighting their role in treatment resistance and therapy management.

Key Points

  • The study aims to characterize BRAF fusions in non-small cell lung cancer and understand their therapeutic implications and resistance mechanisms.
  • Retrospective analysis of 97 NSCLC patients with BRAF fusions
  • Stratification of cases into de novo and acquired subgroups
  • Comparison of genomic and clinical features across different oncogenic driver cohorts
  • Identified 104 unique BRAF fusions with 53 distinct 5' partners
  • Noticed that 65.1% of de novo cases lacked co-occurring drivers
  • Acquired BRAF fusions were primarily observed after EGFR-TKI therapy, indicating resistance
  • Clinical benefit from combined MEK and EGFR inhibition was observed in a patient with specific fusions

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/69d1fd13a79560c99a0a2ee9https://doi.org/10.1158/1538-7445.am2026-2519
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 5341: Real-world landscape of BRAF fusions in chinese patients with lung and colorectal cancers: Insights from 26,248 DNA-NGS and RNA-NGS tests.2026
  2. 2Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets2024 · 3 citations
  3. 3Abstract 4103: Dynamic co-mutation patterns and therapeutic implications in BRAF-altered malignancies: Evidence from AACR Project GENIE2026
  4. 4Targeting rare variants of a pan-cancer target: The landscape of <i>BRAF</i> non-v600 mutations and <i>BRAF</i>fusions from 172,005 adult patients with cancer.2024
  5. 5Data from Tumor-Agnostic Genomic and Clinical Analysis of &lt;i&gt;BRAF&lt;/i&gt; Fusions Identifies Actionable Targets2024